1. Scrip
  2. >>New Products

Pfizer's Mylotarg Rejoins AML Market At $24,600 List Price

 
• By Emily Hayes

CD33 inhibiting drug that was yanked from the market in 2010 due to reports of veno-occlusive disease is now fully approved by the US FDA at a lower recommended dose.

Pfizer Inc.'santibody-drug conjugateMylotarg is set to reenter the US market at the list price of $24,600 for one cycle of treatment, which is all many patients will need, the company said.

The US FDA cleared Mylotarg (gemtuzumab ozagamicin) Sept. 1 for adults with newly-diagnosed, CD33-positive acute myeloid leukemia (AML) and children...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By Lisa Takagi

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.